Assetmark Inc. Sells 947 Shares of Fresenius Medical Care AG (NYSE:FMS)

Assetmark Inc. reduced its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 28.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,433 shares of the company’s stock after selling 947 shares during the quarter. Assetmark Inc.’s holdings in Fresenius Medical Care were worth $52,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Wulff Hansen & CO. lifted its holdings in shares of Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after acquiring an additional 325,439 shares during the period. Triasima Portfolio Management inc. increased its stake in shares of Fresenius Medical Care by 27.4% in the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock valued at $1,631,000 after purchasing an additional 18,360 shares during the last quarter. QRG Capital Management Inc. increased its stake in shares of Fresenius Medical Care by 10.9% in the 2nd quarter. QRG Capital Management Inc. now owns 60,309 shares of the company’s stock valued at $1,151,000 after purchasing an additional 5,946 shares during the last quarter. Creative Planning lifted its position in shares of Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after buying an additional 6,373 shares during the last quarter. Finally, Ritholtz Wealth Management lifted its position in shares of Fresenius Medical Care by 2.5% during the 2nd quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock worth $704,000 after buying an additional 895 shares during the last quarter. 8.25% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $22.14 on Tuesday. The stock’s 50-day moving average is $20.70 and its 200-day moving average is $20.24. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $22.76. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a market cap of $12.99 billion, a P/E ratio of 18.29, a price-to-earnings-growth ratio of 1.02 and a beta of 0.91.

Wall Street Analyst Weigh In

FMS has been the subject of a number of research reports. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company. Truist Financial upped their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Finally, StockNews.com began coverage on shares of Fresenius Medical Care in a research note on Saturday, November 9th. They set a “strong-buy” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.30.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.